Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 11 Sep 2025
Anyone who has taken a yoga class knows how relaxing it can be to set aside the day's worries and focus on breathing, gentle movements, healing stretches and guided meditation, even if just for an hour.
Read Full NewsAripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.
Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.
In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.
1.
A BRAF V600E mutation-positive intrathoracic synovial sarcoma is reported by researchers.
2.
No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer
3.
Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.
4.
An inoperable locally advanced NSCLC trial dubbed "Practice Changing".
5.
CDC Alerts on Dramatic Rise in Human Parvovirus B19
1.
All You Need To Know About Partial Thromboplastin Time (PTT) Test
2.
Machine Learning in Genomic Analysis for Early Lung Cancer Detection: Key Advances and Insights
3.
Survivin as a Key Regulator in Gynecological Cancers: Therapeutic and Prognostic Implications
4.
Rasburicase-Linked Methemoglobinemia in HCC: Risks, Mechanisms, and Management
5.
Unleashing the Inner Predator: Reprogramming Macrophages to Conquer Cancer Immunotherapy
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
Navigating the Complexities of Ph Negative ALL - Part IV
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
5.
Navigating the Complexities of Ph Negative ALL - Part XII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge